Findings

What do systematic reviews say?

10 questions · 10 findings · 4 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 50%Low 1 · 10%Moderate 2 · 20%High 2 · 20%

Adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Adverse events · patients with chronic pancreatitis and pancreatic pain

Pregabalin probably leads to higher adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
RR 1.71 [1.2, 2.43]
1 study · 64 participants
Moderate

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Serious adverse events · patients with chronic pancreatitis and pancreatic pain

Pregabalin showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Pregabalin for decreasing pancreatic pain in chronic pancreatitis 2016 · Cochrane Headline outcomes only
RR 1.76 [0.35, 8.96]
1 study · 64 participants
Low

Serious adverse events · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
Very low

Serious adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1238 participants
Very low

Serious adverse events · patients with fibromyalgia

Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.03 [0.71, 1.49]
4 studies · 2729 participants
Moderate

Withdrawals due to adverse events · patients with fibromyalgia

Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.68 [1.36, 2.07]
5 studies · 3259 participants
High

Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Withdrawals due to adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1874 participants
High